Rodica Morariu-Zamfir

Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma

Anas Younes, Stella Kim, Jorge Romaguera et al. · Journal of Clinical Oncology · 2012 · 167 citations · Full text

Pharmacy, Oncology, Pharmacokinetics +15

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia

Simona Lapusan, María‐Belén Vídriales, Xavier Thomas et al. · Investigational New Drugs · 2011 · 107 citations

Medicine, Oncology, Pharmacology +16

A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL

Natalie Dimier, Paul Delmar, Carol Ward et al. · Blood · 2017 · 82 citations · Full text

Public Health, Biostatistics, Oncology +12

Influence of CD34+ marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukaemia

Rodica Morariu-Zamfir, Vanderson Rocha, A Devergié et al. · Bone Marrow Transplantation · 2001 · 44 citations

Medicine, Hematology, Immunology +16

Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).

Anas Younes, Leo I. Gordon, Stella Kim et al. · Blood · 2009 · 37 citations

Pharmacy, Immunology, Oncology +15